

Retraction

Neuroscience

Retraction of “Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in vitro and in the 3xTg-AD mouse model,” by Karolina J. Janczura, Claude-Henry Volmar, Gregory C. Sartor, Sunil J. Rao, Natalie R. Ricciardi, Guerline Lambert, Shaun P. Brothers, and Claes Wahlestedt, which was first published November 5, 2018; 10.1073/pnas.1805436115 (*Proc. Natl. Acad. Sci. U.S.A.* **115**, E11148–E11157).

The undersigned authors note: “While we believe our findings that AD phenotypes can be reversed by HDAC3 inhibition are correct, we have decided to retract our article due to errors discovered in six out of 28 total figures (including supplementary figures). After discovering the errors, we reanalyzed the relevant data, resulting in the following: Fig. 4 (gain of significance in E and F), Fig. 6 (gain of significance in B and loss of significance in C), Fig. 7 (loss of significance in PFC and gain of significance in CER in B), Fig. 8 (significance only in HIP in B and in ERC in C), Fig. 9 (loss of significance in B and decreased significance in C and D), and *SI Appendix*, Fig. S17 (loss of significance in ERC and gain of significance in CER in B). However, due to the quantity of errors and their impact on the published conclusions, we are retracting the article. We apologize for these oversights and are grateful to the editors and the scientific community for their understanding.”

Claude-Henry Volmar, Gregory C. Sartor, Sunil J. Rao, Natalie R. Ricciardi,
Guerline Lambert, Shaun P. Brothers, and Claes Wahlestedt

This article is distributed under [Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 \(CC BY-NC-ND\)](https://creativecommons.org/licenses/by-nc-nd/4.0/).

Published August 21, 2024.